Live
FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approachCellDecoding the spatiotemporal development of human meningesCellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulationCellPhysiological brain clearance architecture revealed by neuronal protein tracingFierceBiotechASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Endpoints NewsCan AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and moreIlluminaIllumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360BioPharma DiveAt ASCO, Merck makes case for a ‘cornerstone’ cancer drugBioPharma DiveBristol Myers unveils data for one of its next-gen blood cancer drugsClinical OMICsTeclistamab Outperforms Standard Therapy in Relapsed Multiple MyelomaClinical OMICsAI Chatbots Do Not Consistently Deliver Accurate Health ResponsesFierceBiotechLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
BioPharma Dive Apr 13, 2026

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Original
Body unavailable. Use the original source.